DE68921150T2 - Wirkung von hormonen. - Google Patents

Wirkung von hormonen.

Info

Publication number
DE68921150T2
DE68921150T2 DE68921150T DE68921150T DE68921150T2 DE 68921150 T2 DE68921150 T2 DE 68921150T2 DE 68921150 T DE68921150 T DE 68921150T DE 68921150 T DE68921150 T DE 68921150T DE 68921150 T2 DE68921150 T2 DE 68921150T2
Authority
DE
Germany
Prior art keywords
pct
inhibin
sec
host
activin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68921150T
Other languages
English (en)
Other versions
DE68921150D1 (de
Inventor
Kretser David De
David Milne-Robertson
Mark Hedger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
St Vincents Institute of Medical Research
Biotech Australia Pty Ltd
Monash University
Prince Henrys Institute of Medical Research
Original Assignee
St Vincents Institute of Medical Research
Biotech Australia Pty Ltd
Monash University
Prince Henrys Institute of Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Vincents Institute of Medical Research, Biotech Australia Pty Ltd, Monash University, Prince Henrys Institute of Medical Research filed Critical St Vincents Institute of Medical Research
Publication of DE68921150D1 publication Critical patent/DE68921150D1/de
Application granted granted Critical
Publication of DE68921150T2 publication Critical patent/DE68921150T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00Drug, bio-affecting and body treating compositions
    • Y10S424/81Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
  • Lock And Its Accessories (AREA)
DE68921150T 1988-05-31 1989-05-31 Wirkung von hormonen. Expired - Fee Related DE68921150T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPI853488 1988-05-31
AUPJ147088 1988-11-15
PCT/AU1989/000245 WO1989011862A1 (en) 1988-05-31 1989-05-31 Actions of hormones

Publications (2)

Publication Number Publication Date
DE68921150D1 DE68921150D1 (de) 1995-03-23
DE68921150T2 true DE68921150T2 (de) 1995-06-14

Family

ID=25643485

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68921150T Expired - Fee Related DE68921150T2 (de) 1988-05-31 1989-05-31 Wirkung von hormonen.

Country Status (5)

Country Link
US (1) US5196192A (de)
EP (1) EP0368992B1 (de)
AT (1) ATE118351T1 (de)
DE (1) DE68921150T2 (de)
WO (1) WO1989011862A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341617C (en) * 1984-06-08 2011-06-28 Henry George Burger Inhibin isolated from ovarian follicular fluid
US5942220A (en) * 1990-03-16 1999-08-24 Chiron Corporation Inhibitor of cytokine activity and applications thereof
WO1991012334A1 (en) * 1990-02-15 1991-08-22 Cetus Corporation Inhibitor of cytokine activity and applications thereof
CA2104678C (en) 1991-03-11 2002-05-14 Charles M. Cohen Protein-induced morphogenesis
SE502569C2 (sv) * 1991-05-31 1995-11-13 British Tech Group Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit
JPH08501314A (ja) * 1992-09-16 1996-02-13 ジェネンテク,インコーポレイテッド Hgfによる肝臓障害に対する保護
US5658876A (en) * 1994-04-28 1997-08-19 The General Hospital Corporation Activin antagonists as novel contraceptives
JPH11507663A (ja) * 1995-06-09 1999-07-06 イエダ リサーチ アンド デベロツプメント カンパニー リミテツド レストリクチンp/アクチビンaを含む薬学的組成物及びil−6及び/又はil−11のアンタゴニストとしてのその用途
GB2306481A (en) * 1995-10-21 1997-05-07 Univ Manchester Pharmaceutical comprising a stimulator of activin and/or inhibin
AUPO638897A0 (en) * 1997-04-23 1997-05-22 Monash University Modulation of cell growth and methods relating thereto
TW586934B (en) * 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
JPH11196864A (ja) 1998-01-08 1999-07-27 Deinabekku Kenkyusho:Kk 破骨細胞の分化を誘導する方法
EP0974650A1 (de) * 1998-07-22 2000-01-26 University Of Ioannina/Medical School Inhibitoren des Endothelzellwachstums
AU780358B2 (en) * 1999-06-08 2005-03-17 Lorantis Limited Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway
WO2005032578A1 (en) 2003-10-06 2005-04-14 Monash University Therapeutic method

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341617C (en) * 1984-06-08 2011-06-28 Henry George Burger Inhibin isolated from ovarian follicular fluid
AU4437485A (en) * 1984-06-08 1986-01-10 Biotechnology Australia Proprietary Limited Inhibin isolated from ovarian follicular fluid
EP0218717B1 (de) * 1985-04-18 1998-07-15 Biotechnology Australia Pty. Ltd. Rekombinantes inhibin
AU5903986A (en) * 1985-04-18 1986-11-05 Biotechnology Australia Proprietary Limited Recombinant inhibin
AU610821B2 (en) * 1985-04-18 1991-05-30 Inhibin Pty Limited Recombinant inhibin
JPH0637520B2 (ja) * 1985-07-03 1994-05-18 味の素株式会社 ポリペプチド
NZ217727A (en) * 1985-10-03 1990-05-28 Genentech Inc Nucleic acid encoding alpha or b chain of inhibin, its production and compositions containing it
JP2802633B2 (ja) * 1987-01-29 1998-09-24 バイオテクノロジー・オーストラリア・プロプライエタリー・リミテツド たん白
US5032507A (en) * 1987-11-13 1991-07-16 The Salk Institute For Biological Studies Potentiation of erythropoiesis

Also Published As

Publication number Publication date
US5196192A (en) 1993-03-23
EP0368992A1 (de) 1990-05-23
DE68921150D1 (de) 1995-03-23
ATE118351T1 (de) 1995-03-15
EP0368992B1 (de) 1995-02-15
WO1989011862A1 (en) 1989-12-14
EP0368992A4 (en) 1991-04-03

Similar Documents

Publication Publication Date Title
DE68921150D1 (de) Wirkung von hormonen.
BR0007719A (pt) Baff, agentes de bloqueio relacionados e uso dosmesmos no estìmulo e na inibição de células b e deimunoglobulinas em respostas imunológicas
DE69129800T2 (de) Behandlung von menschlichen retrovirus-infektionen mit 2',3'-dideoxyinosin
DE69033487T2 (de) Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol
DK0428038T3 (da) Transdermal administration af 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
BR9608612A (pt) Vacina compreendendo um conjugado de antígeno de polissacarídeo - proteína portadora e proteína portadora livre
ATE110578T1 (de) Von hydrogel angetriebene verabreichungsvorrichtung.
NL300189I1 (nl) Acellulair vaccin.
AU7814498A (en) Multivalent (in ovo) avian vaccine
NO20000378L (no) Anvendelse av MHC klasse II ligander som adjuvantia for vaksinasjon og LAG-3 i kreftbehandling
BR9610679A (pt) Antígenos de leishmania para uso na terapia e disgnose da leishmaniose
ES2115618T3 (es) Uso de anticuerpos anti-icam en la preparacion de un medicamento para el tratamiento del choque por endotoxinas.
FI972703A (fi) Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia
DK0556322T3 (da) Aminosulfonylurinstof-ACAT-inhibitorer
DK0686155T3 (da) Xanthinderivater som adenosin A1-receptor-antagonister
DK0787135T3 (da) Vandopløslige derivater af epipodophyllotoxin, fremgangsmåde til fremstilling deraf og anvendelse som et lægemiddel til beh
DE69010523D1 (de) Kit oder Zusammensetzung zur Vorbeugung oder Behandlung von HIV-1 Infektionen.
DK0835309T3 (da) Vaccine imod infektiøse agenser, præparat til behandling og forebyggelse af HIV infektioner
SE8402199D0 (sv) Pharmazeutisches preparat enthaltend co-dergocrine und einen calcium-antagonisten
DE59006159D1 (de) Verwendung von macrolactonen als antiallergica.
DE3878529D1 (de) Vorrichtung zur behandlung von verstauchungen, insbesondere der sprunggelenke sowie zur vermeidung von dabei auftretenden bestimmten komplikationen.
DE3879837T2 (de) Pharmazeutische praeparate zur behandlung von zereberalen psycho-organischen syndromen.
DE3776662D1 (de) Pharmazeutische zusammensetzungen zur behandlung von hyperproliferativer hautkrankheit.
DE68914886D1 (de) Mittel zur Behandlung von Raynaud's Krankheit.
DE3789760T2 (de) Orale Hyposensibilisierung bei der Behandlung von Allergien.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee